scholarly journals In Situ Photopolymerization of Acrylamide Hydrogel to Coat Cellulose Acetate Nanofibers for Drug Delivery System

Polymers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 1863
Author(s):  
Mohamed F. Attia ◽  
Ahmed S. Montaser ◽  
Md Arifuzzaman ◽  
Megan Pitz ◽  
Khouloud Jlassi ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cellulose Acetate ◽  
Electrospinning Process ◽  
Release Profile ◽  
Burst Release ◽  
Spectroscopic Techniques ◽  
Kinetic Release ◽  
Hydrogel Polymer ◽  
Poly Acrylamide

In this study we developed electrospun cellulose acetate nanofibers (CANFs) that were loaded with a model non-steroidal anti-inflammatory drug (NSAID) (ibuprofen, Ib) and coated with poly(acrylamide) (poly-AAm) hydrogel polymer using two consecutive steps: an electrospinning process followed by photopolymerization of AAm. Coated and non-coated CANF formulations were characterized by several microscopic and spectroscopic techniques to evaluate their physicochemical properties. An analysis of the kinetic release profile of Ib showed noticeable differences due to the presence or absence of the poly-AAm hydrogel polymer. Poly-AAm coating facilitated a constant release rate of drug as opposed to a more conventional burst release. The non-coated CANFs showed low cumulative drug release concentrations (ca. 35 and 83% at 5 and 10% loading, respectively). Conversely, poly-AAm coated CANFs were found to promote the release of drug (ca. 84 and 99.8% at 5 and 10% loading, respectively). Finally, the CANFs were found to be superbly cytocompatible.

Sucrose Acetate Isobutyrate as an In situ Forming Implant for Sustained Release of Local Anesthetics

2019 ◽  
Vol 16 (4) ◽  
pp. 331-340
Author(s):  
Hanmei Li ◽  
Yuling Xu ◽  
Yuna Tong ◽  
Yin Dan ◽  
Tingting Zhou ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Sustained Release ◽  
Local Anesthetics ◽  
Subcutaneous Injection ◽  
In Vitro Release ◽  
Pharmacokinetic Analysis ◽  
Burst Release

Objective: In this study, an injectable Sucrose Acetate Isobutyrate (SAIB) drug delivery system (SADS) was designed and fabricated for the sustained release of Ropivacaine (RP) to prolong the duration of local anesthesia. Methods: By mixing SAIB, RP, and N-methyl-2-pyrrolidone, the SADS was prepared in a sol state with low viscosity before injection. After subcutaneous injection, the pre-gel solution underwent gelation in situ to form a drug-released depot. Result: The in vitro release profiles and in vivo pharmacokinetic analysis indicated that RP-SADS had suitable controlled release properties. Particularly, the RP-SADS significantly reduced the initial burst release after subcutaneous injection in rats. Conclusion: In a pharmacodynamic analysis of rats, the duration of nerve blockade was prolonged by over 3-fold for the RP-SADS formulation compared to RP solution. Additionally, RP-SADS showed good biocompatibility in vitro and in vivo. Thus, the SADS-based depot technology is a safe drug delivery strategy for the sustained release of local anesthetics with long-term analgesia effects.

scholarly journals l-Buthionine Sulfoximine Detection and Quantification in Polyurea Dendrimer Nanoformulations

Molecules ◽  
2019 ◽  
Vol 24 (17) ◽  
pp. 3111 ◽  
Author(s):  
Pedro Mota ◽  
Rita F. Pires ◽  
Jacinta Serpa ◽  
Vasco D. B. Bonifácio
Keyword(s):  
Drug Delivery ◽  
Nmr Spectroscopy ◽  
Cancer Cells ◽  
Drug Delivery Systems ◽  
Buthionine Sulfoximine ◽  
Release Profile ◽  
Analytical Tools ◽  
Sensitive Method ◽  
Detection And Quantification

l-Buthionine sulfoximine (l-BSO) is an adjuvant drug that is reported to increase the sensitivity of cancer cells to neoplastic agents. Dendrimers are exceptional drug delivery systems and l-BSO nanoformulations are envisaged as potential chemotherapeutics. The absorption of l-BSO at a low wavelength limits its detection by conventional analytical tools. A simple and sensitive method for l-BSO detection and quantification is now reported. In this study, l-BSO was encapsulated in a folate-targeted generation four polyurea dendrimer (PUREG4-FA2) and its release profile was followed for 24 h at pH 7.4 and 37 °C. The protocol uses in situ l-BSO derivatization, by the formation of a catechol-derived orto-quinone, followed by visible detection of the derivative at 503 nm. The structure of the studied l-BSO derivative was assessed by NMR spectroscopy.

Antibacterial Agent-Incorporated Cholesterol Phase Inversion-Based In Situ Forming Matrix for Crevicular Pocket Delivery

2020 ◽  
Vol 859 ◽  
pp. 107-112
Author(s):  
Orn Setthajindalert ◽  
Khine Sabel Aung ◽  
Juree Charoenteeraboon ◽  
Arissarakorn Sirinamaratana ◽  
Thawatchai Phaechamud
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Antibacterial Agent ◽  
Phase Inversion ◽  
Gingival Crevicular Fluid ◽  
Diffusion Method ◽  
Burst Release ◽  
Doxycycline Hyclate

Phase inversion in situ forming matrix is one of the promising drug delivery systems for periodontitis treatment owing to the prospective high antimicrobial agent level in the gingival crevicular fluid. Typically, this drug delivery system is a fluid polymeric solution that could change simultaneously to matrix-like after injection into aqueous physiological environment. The main propose of the current study was to achieve successful development of antibacterial agent-incorporated cholesterol phase inversion in situ forming matrix for crevicular pocket delivery. In this study, cholesterol was used as a fat matrix former, while N-methyl pyrrolidone (NMP) was used as the solvent and menthol was used as co-solvent. The 10%w/w metronidazole or doxycycline hyclate was employed as the active compounds. The developed formula were evaluated for viscosity and rheological behavior, antimicrobial activity using cup agar diffusion method and in vitro drug release using dialysis tube method. The consistency index from rheological test of doxycycline hyclate and metronidazole-loaded in situ forming matrices was not significantly different (p<0.05). Interestingly, the viscosity of all formula was quite low; thus, this characteristic provoked an ease of injection. They inhibited against Porphyromonasgingivalis efficiently more than cholesterol in situ forming matrix base (p<0.05). Drug release from systems loaded with doxycycline hyclate and metronidazole were rapid and nearly not different. Owing to the apparent efficiently inhibition against Porphyromonasgingivalis the in situ forming matrix loading doxycline hyclate was selected for further development to minimize the burst release and to prolong the drug release.

Biodegradable Chitosan-Silicate Porous Hybrids for Drug Delivery

2007 ◽  
Vol 361-363 ◽  
pp. 1219-1222 ◽  
Author(s):  
Yuki Shirosaki ◽  
Kanji Tsuru ◽  
Satoshi Hayakawa ◽  
Akiyoshi Osaka
Keyword(s):  
Drug Delivery ◽  
Cytochrome C ◽  
Drug Delivery Systems ◽  
Freeze Drying ◽  
Saline Solution ◽  
Release Profile ◽  
Burst Release ◽  
Phosphate Buffer Saline Solution ◽  
Cytochrome C Release ◽  
Porous Chitosan

Porous chitosan-silicate hybrids were prepared by freeze-drying the precursor sol solutions synthesized from chitosan and 3-glycidoxypropyltrimethoxysilane (GPTMS). Degradability of and the release of cytochrome C in to phosphate buffer saline solution (PBS) were examined as a function of the GPTMS content. The hybrids were less degradable with larger GPTMS contents, and the cytochrome C release profile was so controllable as to give either burst release or slow one due to the GPTMS content. Thus, the present porous chitosan-silicate hybrids were considered applicable to drug delivery systems.

Scaffolds for Drug Delivery in Tissue Engineering

2008 ◽  
Vol 1 (2) ◽  
pp. 113-123 ◽  
Author(s):  
Vikas V. Gaikwad ◽  
Abasaheb B. Patil ◽  
Madhuri V. Gaikwad
Keyword(s):  
Drug Delivery ◽  
Tissue Engineering ◽  
Heart Diseases ◽  
Cartilage Regeneration ◽  
Tissue Growth ◽  
The Body ◽  
Patient Specific ◽  
In Situ Gel ◽  
Heart Muscle Cells

Scaffolds are used for drug delivery in tissue engineering as this system is a highly porous structure to allow tissue growth.  Although several tissues in the body can regenerate, other tissue such as heart muscles and nerves lack regeneration in adults. However, these can be regenerated by supplying the cells generated using tissue engineering from outside. For instance, in many heart diseases, there is need for heart valve transplantation and unfortunately, within 10 years of initial valve replacement, 50–60% of patients will experience prosthesis associated problems requiring reoperation. This could be avoided by transplantation of heart muscle cells that can regenerate. Delivery of these cells to the respective tissues is not an easy task and this could be done with the help of scaffolds. In situ gel forming scaffolds can also be used for the bone and cartilage regeneration. They can be injected anywhere and can take the shape of a tissue defect, avoiding the need for patient specific scaffold prefabrication and they also have other advantages. Scaffolds are prepared by biodegradable material that result in minimal immune and inflammatory response. Some of the very important issues regarding scaffolds as drug delivery systems is reviewed in this article.

Injectable in-situ Forming Depot Of Doxycycline Hyclate/α-Cyclodextrin Complex using PLGA for Periodontitis Treatment: Preparation, Charac-terization, and In-Vitro Evaluation

2020 ◽  
Vol 17 ◽  
Author(s):  
Elham Khodaverdi ◽  
Farhad Eisvand ◽  
Mohammad Sina Nezami ◽  
Seyedeh Nesa Rezaeian Shiadeh ◽  
Hossein Kamali ◽  
...  
Keyword(s):  
Complex Form ◽  
Docking Studies ◽  
Morphological Properties ◽  
Burst Release ◽  
Cyclodextrin Complex ◽  
Doxycycline Hyclate ◽  
Scanning Calorimetry ◽  
In Situ Forming

Background:: Doxycycline (DOX) is used in treating a bacterial infection, especially for periodontitis treatment. Objective: To reduce irritation of DOX for subgingival administration and increase the chemical stability and against enzy-matic, the complex of α-cyclodextrin with DOX was prepared and loaded into injectable in situ forming implant based on PLGA. Methods:: FTIR, molecular docking studies, X-ray diffraction, and differential scanning calorimetry was performed to char-acterize the DOX/α-cyclodextrin complex. Finally, the in-vitro drug release and modeling, morphological properties, and cellular cytotoxic effects were also evaluated. Results:: The stability of DOX was improved with complex than pure DOX. The main advantage of the complex is the al-most complete release (96.31 ± 2.56 %) of the drug within 14 days of the implant, whereas in the formulation containing the pure DOX and the physical mixture the DOX with α-cyclodextrin release is reached to 70.18 ± 3.61 % and 77.03 ± 3.56 %, respectively. This trend is due to elevate of DOX stability in the DOX/ α-cyclodextrin complex form within PLGA implant that confirmed by the results of stability. Conclusion:: Our results were indicative that the formulation containing DOX/α-cyclodextrin complex was biocompatible and sustained-release with minimum initial burst release.

Development, Evaluation and Optimization of Osmotic Controlled Tablets of Aceclofenac for Rheumatoid Arthritis Management

2019 ◽  
Vol 9 (1) ◽  
pp. 29-36
Author(s):  
Bijaya Ghosh ◽  
Niraj Mishra ◽  
Preeta Bose ◽  
Moumita D. Kirtania
Keyword(s):  
Rheumatoid Arthritis ◽  
Polyethylene Glycol ◽  
Sodium Chloride ◽  
Cellulose Acetate ◽  
Hydroxypropyl Methylcellulose ◽  
Release Profile ◽  
Polyethylene Glycol 400 ◽  
Permeable Membrane ◽  
Cumulative Release ◽  
The Core

Objective: Rheumatoid arthritis is a dreaded disease, characterized by pain, inflammation and stiffness of joints, leading to severe immobility problems. The disease shows circadian variation and usually gets aggravated in early morning hours. Aceclofenac, a BCS Class II compound is routinely used in the treatment of pain and inflammation associated with rheumatoid arthritis. The objective of this study was to develop an osmotic delivery system of Aceclofenac that after administration at bedtime would deliver the drug in the morning hours. </P><P> Methods: A series of osmotically controlled systems of aceclofenac was developed by using lactose, sodium chloride and hydroxypropyl methylcellulose K100M as osmogens. Cellulose acetate (2% w/v in acetone) with varying concentrations of polyethylene glycol-400 was used as the coating polymer to create semi permeable membrane and dissolution was carried out in 290 mOsm phosphate buffer. Formulation optimization was done from four considerations: cumulative release at the end of 6 hours (lag time), cumulative release at the end of 7 hours (burst time), steady state release rate and completeness of drug release. </P><P> Results: A formulation having swelling polymer hydroxypropyl methylcellulose in the core and lactose and sodium chloride as osmogens, polyethylene glycol-400 (16.39 %) as pore former, with a coating weight of 5% was a close fit to the target release profile and was chosen as the optimum formulation. Conclusion: Aceclofenac tablets containing lactose, HPMC and sodium chloride in the core, given a coating of cellulose acetate and PEG-400 (5% wt gain), generated a release profile for optimum management of rheumatoid arthritic pain.

Sign in / Sign up

Export Citation Format

Share Document